Recruiting

Testing a new preventive treatment for severe COVID-19

Plain-English translation of NCT07445971 on ClinicalTrials.gov ↗ · Source last updated May 2026 · Translation generated June 2026 · How we translate trials

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

What is this trial?

This is the first study in humans to test , a new preventive treatment designed to help protect against severe COVID-19. Researchers want to understand whether the medication is safe and how well it works when given by injection. The study will track participants' health and measure how their bodies respond to the treatment.

COVID-19 remains a serious threat, especially for people with conditions like diabetes, heart disease, or chronic lung disease. This trial is exploring a new preventive approach to help protect these vulnerable groups from developing severe illness.

Do you qualify?

You likely qualify if…

you are between 18 and 64 years old
you are in good overall health (for the healthy adult group) or you have at least one condition that puts you at higher risk for severe COVID-19, such as asthma, diabetes, heart disease, chronic kidney disease, or cystic fibrosis
you are stable with your health conditions and have not been hospitalized in the past year
if you are a woman who could become pregnant, you have a negative pregnancy test and agree to use effective birth control during the study
you are willing to attend study visits and follow all study procedures

You likely don't qualify if…

you have tested positive for COVID-19 or received a COVID-19 vaccine before the study starts
you have active hepatitis B or hepatitis C infections
you have abnormal heart rhythm, blood pressure, or lab results at screening
you have received other monoclonal antibody treatments or blood-derived products for COVID-19 protection within 6 months
you are pregnant, breastfeeding, or unwilling to use birth control

What participation looks like

You will receive either the new medication or a placebo (inactive treatment) by injection — either under the skin, into a muscle, or through an IV line. Some participants will receive a single dose, while others will receive an initial dose followed by a second dose three months later. You'll have follow-up visits to check your health, provide blood samples, and report any side effects you experience.

AI-generated summary from trial data · Jun 9, 2026 · Not medical advice

Trial locations(2 sites)

United States

TrialMed Clinical Research Unit, Las Vegas, Nevada

TrialMed Clinical Research Unit, Austin, Texas